Skip to main content

Advertisement

Table 1 Patient population characteristics

From: Burden of illness and quality of life in patients being treated for seasonal allergic rhinitis: a cohort survey

  Total FF MF FP
  N=452 N=229 N=108 N=115
Age (Mean, (SD)) 36.2 (13.9) 36.5 (13.7) 35.8 (13.7) 36.1 (14.6)
Gender (% females) 52.2% 49.8% 53.7% 55.7%
Body mass index (Mean, (SD)) 24.1 (3.7) 24.1 (3.8) 24.3 (3.9) 23.9 (3.5)
Country of origin (N, %):     
  France 163 (36.1%) 82 (35.8%) 38 (35.2%) 43 (37.4%)
  Germany 174 (38.5%) 88 (38.4%) 43 (39.8%) 43 (37.4%)
  Spain 115 (25.4%) 59 (25.8%) 27 (25.0%) 29 (25.2%)
ARIA severity (N, %):     
  Mild intermittent 54 (12.2%) 29 (12.9%) 10 (9.6%) 15 (13.2%)
  Moderate/severe intermittent 147 (33.3%) 81 (36.2%) 38 (36.5%) 28 (24.6%)
  Moderate/severe persistent 241 (54.5%) 114 (50.9%) 56 (53.8%) 71 (62.3%)
Number of concomitant conditions reported in the previous 3 months (mean, SD) 0.96 (1.14) 0.96 (1.07) 1.00 (1.25) 0.92 (1.16)
Number of concomitant medications taken in the previous 3 months (mean, SD) 1.60 (0.67) 1.61 (0.67) 1.57 (0.61) 1.60 (0.74)
Number of patients who ever experienced both ocular and nasal symptoms (N, %) 324 (71.7%) 162 (70.7%) 81 (75.0%) 81 (70.4%)
  1. FF: Fluticasone furoate; FP: Fluticasone propionate; MF: Mometasone furoate; SD: Standard Deviation; N: Number of patients.